Skip to main
OPTN
OPTN logo

OptiNose (OPTN) Stock Forecast & Price Target

OptiNose (OPTN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 13%
Buy 50%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

OptiNose Inc. demonstrates a markedly positive financial outlook, with projected revenue for XHANCE anticipated to rise from $94.7 million in 2024 to $389.2 million by 2032, highlighting the product's significant growth potential in treating chronic rhinosinusitis (CS) and nasal polyps. The company has optimized its sales and distribution strategies, resulting in a substantial reduction of over 30% in operating expenses in 2023 compared to the previous year, indicating enhanced business efficiency while maintaining prescription volume. Furthermore, successful trial outcomes, including statistically significant symptom improvement and potential label expansion for XHANCE, position the company advantageously in a market where CS is diagnosed considerably more frequently than nasal polyps, thereby broadening its commercial reach.

Bears say

OptiNose Inc. faces several fundamental challenges that contribute to a negative outlook on its stock, particularly concerning the market potential for its primary product, XHANCE. The company risks failing to achieve peak commercial revenue projections due to limitations related to market size, penetration rates, and pricing dynamics, along with the potential inability to secure essential capital resources for ongoing operations. Additionally, challenges related to intellectual property protection and a limited focus on specialty prescription growth could further hinder the company's competitive positioning and overall commercial success.

OptiNose (OPTN) has been analyzed by 8 analysts, with a consensus rating of Buy. 13% of analysts recommend a Strong Buy, 50% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptiNose and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptiNose (OPTN) Forecast

Analysts have given OptiNose (OPTN) a Buy based on their latest research and market trends.

According to 8 analysts, OptiNose (OPTN) has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptiNose (OPTN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.